Teacher Retirement System of Texas Buys New Stake in Agios Pharmaceuticals, Inc. (AGIO)
Teacher Retirement System of Texas bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,370 shares of the biopharmaceutical company’s stock, valued at approximately $225,000.
A number of other institutional investors and hedge funds have also made changes to their positions in AGIO. QS Investors LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth about $144,000. Cubist Systematic Strategies LLC raised its position in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares during the last quarter. Aperio Group LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $206,000. S&CO Inc. acquired a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $227,000. Finally, Parametrica Management Ltd acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $228,000. Institutional investors own 92.64% of the company’s stock.
In related news, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54. Following the completion of the transaction, the insider now owns 8,410 shares of the company’s stock, valued at $521,335.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $60.88, for a total transaction of $243,520.00. Following the transaction, the director now directly owns 82,394 shares of the company’s stock, valued at approximately $5,016,146.72. The disclosure for this sale can be found here. Insiders have sold 178,908 shares of company stock valued at $12,163,839 in the last ninety days. 10.55% of the stock is currently owned by company insiders.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at $61.26 on Friday. Agios Pharmaceuticals, Inc. has a 52-week low of $39.24 and a 52-week high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same quarter in the prior year, the business posted ($1.63) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year. equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.
A number of equities analysts have recently weighed in on AGIO shares. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank Of Canada started coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price objective for the company. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Credit Suisse Group boosted their price objective on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $75.70.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.